Cocrystal Pharma Inc (COCP) ニュース

Form 8-K - Current report

Cocrystal Pharma Reports Phase 1 Results with Oral, Broad-Acting Antiviral Drug CDI-988 for Prophylaxis and Treatment of Norovirus, Coronaviruses and Other Viral Infections

Data show favorable safety and tolerability with dosing up to 800 mg for 10 daysPlans to initiate human...

Form 8-K - Current report

Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344

Data support favorable safety and tolerability profile with no serious adverse events (SAEs) or study-related...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Cocrystal Pharma Reports Third Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

BOTHELL, Wash., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the...

Form 8-K - Current report

Cocrystal Pharma’s Co-CEOs Highlight Pioneering Approach to Antiviral Drug Candidates Targeting Influenza and Coronaviruses as Fall Flu and COVID Season Begins

The Company’s antiviral candidate for seasonal and pandemic influenza shows in vitro activity against the avian...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Cocrystal Pharma Advances Oral Pan-Viral Protease Inhibitor CDI-988 into Phase 1 Multiple-Ascending Dose Cohorts

BOTHELL, Wash., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the...